Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Kalaris Therapeutics, a clinical-stage biotech company focused on retinal disease treatments, announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference. The company will discuss its lead candidate, TH103, an investigational dual-action anti-VEGF biologic in Phase 1b/2 trials for neovascular Age-related Macular Degen…